Olema Pharmaceuticals, Inc. Net Income Loss

Quick Answer

Olema Pharmaceuticals, Inc. reported Net Income Loss of -$162.45 million for the year ending 2025.

  • Olema Pharmaceuticals, Inc. showed a decrease of -25.5% in Net Income Loss from 2024 to 2025.
  • This data is from Olema Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Olema Pharmaceuticals, Inc.'s Net Income Loss has declined by 3,663.9%.
  • Historical annual values: Fiscal year 2025: -$162.45 million | Fiscal year 2024: -$129.47 million | Fiscal year 2023: -$96.66 million | Fiscal year 2022: -$104.79 million | Fiscal year 2021: -$71.10 million | Fiscal year 2020: -$22.12 million | Fiscal year 2019: -$4.32 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: